In the SITAGRAMI trial (NCT00650143), DPP4 inhibition in high doses was shown to increase the biological half-life of SDF1α and resulted in an improved cardial regeneration after myocardial infarction [32]. This evidence concerns the gene CXCL12 and myocardial infarction.